Permeability of olmesartan medoxomil from lipid based and suspension formulations using an optimized HDM-PAMPA model

References

• Adson A, Burton PS, Raub TJ, Barsuhn CL, Audus KL, Ho NFH. 1995. Passive diffusion of weak organic electrolytes across Caco‐2 cell monolayers: Uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci. 84(10):1197–1204.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res An Off J Am Assoc Pharm Sci. 12(3):413–420.
   Google Scholar
• Anderson BW, Levine AS, Levitt DG, Kneip JM, Levitt MD. 1988. Physiological measurement of luminal stirring in perfused rat jejunum. Am J Physiol. 254(6):G843–G848.
   PubMedGoogle Scholar
• Artursson P, Karlsson J. 1991. [Database] Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 175(3):880–885.
   PubMed Web of Science ®Google Scholar
• Avdeef A, Artursson P, Neuhoff S, Lazorova L, Gråsjö J, Tavelin S. 2005. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKaflux method. Eur J Pharm Sci. 24(4):333–349.
   PubMed Web of Science ®Google Scholar
• Avdeef A, Strafford M, Block E, Balogh MP, Chambliss W, Khan I. 2001. Drug absorption in vitro model: filter-immobilized artificial membranes: 2. Studies of the permeability properties of lactones in Piper methysticum Forst. Eur J Pharm Sci. 14(4):271–280.
   PubMed Web of Science ®Google Scholar
• Beg S, Sharma G, Thanki K, Jain S, Katare OP, Singh B. 2015. Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation. Int J Pharm. 493(1–2):466–482.
   PubMedGoogle Scholar
• Buckley ST, Fischer SM, Fricker G, Brandl M. 2012. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci. 45(3):235–250.
   PubMed Web of Science ®Google Scholar
• Bujard A, Petit C, Carrupt PA, Rudaz S, Schappler J. 2017. HDM-PAMPA to predict gastrointestinal absorption, binding percentage, equilibrium and kinetics constants with human serum albumin and using 2 end-point measurements. Eur J Pharm Sci. 97:143–150.
   PubMed Web of Science ®Google Scholar
• Bujard A, Sol M, Carrupt PA, Martel S. 2014. Predicting both passive intestinal absorption and the dissociation constant toward albumin using the PAMPA technique. Eur J Pharm Sci. 63:36–44.
   PubMed Web of Science ®Google Scholar
• Camenisch G, Folkers G, Van De Waterbeemd H. 1997. Comparison of passive drug transport through Caco-2 cells and artificial membranes. Int J Pharm. 147:61–70.
   Google Scholar
• Cecchelli R, Dehouck B, Descamps L, Fenart L, Buée-Scherrer V, Duhem C, Lundquist S, Rentfel M, Torpier G, Dehouck MP, et al. 1999. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Delivery Rev. 36(2–3):165–178.
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 13(2):123–133.
   PubMed Web of Science ®Google Scholar
• Dams I, Ostaszewska A, Puchalska M, Chmiel J, Cmoch P, Bujak I, Białońska A, Szczepek W. 2015. Synthesis and physicochemical characterization of the process-related impurities of olmesartan medoxomil. Do 5-(biphenyl-2-yl)-1-triphenylmethyltetrazole intermediates in Sartan syntheses exist? Molecules. 20(12):21346–21363.
   PubMed Web of Science ®Google Scholar
• Fade V. 1998. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci. 87(12):1604–1607.
   PubMed Web of Science ®Google Scholar
• FDA. 1997. Guidance for ındustry dissolution testing of ımmediate evaluation. USA: FDA.
   Google Scholar
• Gorain B, Choudhury H, Kundu A, Sarkar L, Karmakar S, Jaisankar P, Pal TK. 2014. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Colloids Surf B Biointerfaces. 115:286–294.
   PubMed Web of Science ®Google Scholar
• Gutknecht J, Tosteson DC. 1973. Diffusion of weak acids across lipid bilayer membranes: effects of chemical reactions in the unstirred layers. Science. 182(4118):1258–1261.
   PubMed Web of Science ®Google Scholar
• Han M, Fu S, Gao J-Q, Fang X-L. 2009. Evaluation of intestinal absorption of ginsenoside Rg1 ıncorporated in microemulison using parallel artificial membrane permeability assay. Biol Pharm Bull. 32(6):1069–1074.
   PubMed Web of Science ®Google Scholar
• Ho NFH, Raub TJ, Burton PS, Barsuhn CL, Adson A, Audus KL, Borchardt RT. 1999. Transport processes in pharmaceutical systems. USA: CRC Press.
   Google Scholar
• International Conference on Harmonization. 2005. ICH topic Q2 (R1) validation of analytical procedures : text and methodology. International Conference on Harmonization, London, UK.
   Google Scholar
• Kansy M, Avdeef A, Fischer H. 2004. Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. Drug Discov Today Technol. 1(4):349–355.
   PubMedGoogle Scholar
• Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem. 41(7):1007–1010.
   PubMed Web of Science ®Google Scholar
• Karlsson J, Artursson P. 1991. A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial (Caco-2) cells grown in permeable filter chambers. Int J Pharm. 71(1–2):55–64
   Google Scholar
• Kogan A, Kesselman E, Danino D, Aserin A, Garti N. 2008. Viability and permeability across Caco-2 cells of CBZ solubilized in fully dilutable microemulsions. Colloids Surf B Biointerfaces. 66(1):1–12.
   PubMed Web of Science ®Google Scholar
• Komesli Y, Burak Ozkaya A, Ugur Ergur B, Kirilmaz L, Karasulu E. 2019. Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability. Drug Dev Ind Pharm. 45(8):1292–1305.
   PubMed Web of Science ®Google Scholar
• Komesli Y, Yildirim Y, Karasulu E. 2020. Visualisation of real-time oral biodistribution of fluorescent labeled self-microemulsifying drug delivery system of olmesartan medoxomil using optical imaging method. Drug Metab Pharmacokinet. 36:100365.
   PubMed Web of Science ®Google Scholar
• Lennernäs H. 1998. Human intestinal permeability. J Pharm Sci. 87(4):403–410.
   PubMed Web of Science ®Google Scholar
• Levitt MD, Furne JK, Strocchi A, Anderson BW, Levitt DG. 1990. Physiological measurement of luminal stirring in the dog and human small bowel. J Clin Invest. 86(5):1540–1547.
   PubMed Web of Science ®Google Scholar
• Markovic BD, Vladimirov SM, Cudina OA, Odovic JV, Karljikovic-Rajic KD. 2012. Karljikovic–Rajic KD. A PAMPA assay as fast predictive model of passive human skin permeability of new synthesized corticosteroid C-21 esters. Molecules. 17(1):480–491.
   PubMed Web of Science ®Google Scholar
• Masungi C, Mensch J, Van Dijck A, Borremans C, Willems B, Mackie C. 2008. Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates. Pharmazie. 63(3):194–199.
   PubMed Web of Science ®Google Scholar
• MultiScreen IP Filter Plate. MultiScreen IP filter plate, 0.45 µm, clear, non-sterile This clear 96 well filter plate has a hydrophobic PVDF membrane used for PAMPA. | Sigma-Aldrich [Internet]. Multiscreen IP Filter Plate; [accessed 2020 Dec 25]. https://www.sigmaaldrich.com/catalog/product/mm/maipntr10?lang=en&region=TR.
   Google Scholar
• Nielsen PE, Avdeef A. 2004. PAMPA – a drug absorption in vitro model: 8. Apparent filter porosity and the unstirred water layer. Eur J Pharm Sci. 22(1):33–41.
   PubMed Web of Science ®Google Scholar
• Obata K, Sugano K, Machida M, Aso Y. 2004. Biopharmaceutics classification by high throughput solubility assay and PAMPA. Drug Dev Ind Pharm. 30(2):181–185.
   PubMed Web of Science ®Google Scholar
• Okur NU, Ege MA, Karasulu Y. 2014. Preparatİon and characterization of naproxen loaded microemulsion formulations for dermal application. Int J Pharm. 4(4):33–42.
   Google Scholar
• Ottaviani G, Martel S, Carrupt PA. 2006. Parallel artificial membrane permeability assay: A new membrane for the fast prediction of passive human skin permeability. J Med Chem. 49(13):3948–3954.
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Wendelspiess S, Alvarez-Sánchez R. 2015. Importance of critical micellar concentration for the prediction of solubility enhancement in biorelevant media. Mol Pharm. 12(4):1171–1179.
   PubMedGoogle Scholar
• Reis JM, Dezani AB, Pereira TM, Avdeef A, Serra CHR. 2013. Lamivudine permeability study: a comparison between PAMPA, ex vivo and in situ single-pass intestinal perfusion (SPIP) in rat jejunum. Eur J Pharm Sci. 48(4–5):781–789.
   PubMed Web of Science ®Google Scholar
• Ruell JA, Tsinman KL, Avdeef A. 2003. PAMPA – a drug absorption in vitro model: 5. Unstirred water layer in iso-pH mapping assays and pKaflux – optimized design (pOD-PAMPA). Eur J Pharm Sci. 20(4–5):393–402.
   PubMed Web of Science ®Google Scholar
• Shabir GA. 2004. HPLC method development and validation for pharmaceutical analysis. Pharm Technol Eur. 16:37–49.
   Google Scholar
• Sinkó B, Garrigues TM, Balogh GT, Nagy ZK, Tsinman O, Avdeef A, Takács-Novák K. 2012. Skin-PAMPA: a new method for fast prediction of skin penetration. Eur J Pharm Sci. 45(5):698–707.
   PubMed Web of Science ®Google Scholar
• Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, Terada K. 2001. Optimized conditions of bio-mimetic artificial membrane permeation assay. Int J Pharm. 228(1–2):181–188.
   PubMed Web of Science ®Google Scholar
• Teksin ZS, Hom K, Balakrishnan A, Polli JE. 2006. Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. J Control Release. 116(1):50–57.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). 2000. Guidance for industry. Analytical procedures and methods validation. Chemistry, manufacturing, and controls documentation. Draft Guidance. USA: US Food and Drug Administration (FDA).
   Google Scholar
• Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 45(12):2615–2623.
   PubMed Web of Science ®Google Scholar
• Wohnsland F, Faller B. 2001. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem. 44(6):923–930.
   PubMed Web of Science ®Google Scholar
• Yu H, Wang Q, Sun Y, Shen M, Li H, Duan Y. 2015. A new PAMPA model proposed on the basis of a synthetic phospholipid membrane. PLOS ONE. 10(2):e0116502.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Polyakov NE, Chistyachenko YS, Khvostov MV, Frolova TS, Tolstikova TG, Dushkin AV, Su W. 2018. Preparation of curcumin self-micelle solid dispersion with enhanced bioavailability and cytotoxic activity by mechanochemistry. Drug Deliv. 25(1):198–209.
   PubMed Web of Science ®Google Scholar
• Zhu C, Jiang L, Chen TM, Hwang KK. 2002. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem. 37(5):399–407.
   PubMed Web of Science ®Google Scholar